Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2019 1
2020 2
2021 3
2022 1
2023 20
2024 41
2025 48
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G. Lederman S, et al. Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13. Lancet. 2023. PMID: 36924778 Clinical Trial.
This study investigated the safety and efficacy of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. ...INTERPRETATION: Data support the clinical use of fezolinetant as a non-hormonal treatment for va …
This study investigated the safety and efficacy of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms …
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C, Lee M, Santoro N. Johnson KA, et al. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1981-1997. doi: 10.1210/clinem/dgad058. J Clin Endocrinol Metab. 2023. PMID: 36734148 Free PMC article. Clinical Trial.
CONTEXT: Vasomotor symptoms (VMS) are common, bothersome, and can persist for years before and after menopause. ...Serious treatment-emergent adverse events were infrequent, reported by 2%, 1%, and 0% of those receiving fezolinetant 30 mg, fezolinetant …
CONTEXT: Vasomotor symptoms (VMS) are common, bothersome, and can persist for years before and after menopause. ...Serious tre …
Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
Depypere H, Lademacher C, Siddiqui E, Fraser GL. Depypere H, et al. Expert Opin Investig Drugs. 2021 Jul;30(7):681-694. doi: 10.1080/13543784.2021.1893305. Epub 2021 Jul 12. Expert Opin Investig Drugs. 2021. PMID: 33724119 Free article. Review.
There is therefore a need for safe, effective non-hormonal therapy for relief of menopausal vasomotor symptoms (VMS).Areas covered: This narrative review summarizes the dataset accrued for fezolinetant, a neurokinin-3 receptor (NK3R) antagonist in clinical de …
There is therefore a need for safe, effective non-hormonal therapy for relief of menopausal vasomotor symptoms (VMS).Areas cov …
Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.
Menegaz de Almeida A, Oliveira P, Lopes L, Leite M, Morbach V, Alves Kelly F, Barros Í, Aquino de Moraes FC, Prevedello A. Menegaz de Almeida A, et al. Obstet Gynecol. 2025 Mar 1;145(3):253-261. doi: 10.1097/AOG.0000000000005812. Epub 2025 Jan 2. Obstet Gynecol. 2025. PMID: 39746208
The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor symptoms, and menopause. METHODS OF STUDY SELECTION: Only RCTs comparing fezolinetant and elinzanetant with placebo for …
The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor …
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD. Neal-Perry G, et al. Obstet Gynecol. 2023 Apr 1;141(4):737-747. doi: 10.1097/AOG.0000000000005114. Epub 2023 Mar 9. Obstet Gynecol. 2023. PMID: 36897180 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the safety, tolerability, and effect of fezolinetant on endometrial health over 52 weeks. METHODS: We conducted a phase 3, randomized, double-blind, 52-week safety study (SKYLIGHT 4 [Study to Find Out How Safe Long-term Treatment With Fezolinetant …
OBJECTIVE: To evaluate the safety, tolerability, and effect of fezolinetant on endometrial health over 52 weeks. METHODS: We conducte …
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A, Ajmera M, Gao E, Patterson-Lomba O, Zhao A, Mancuso S, Siddiqui E, Kagan R. Morga A, et al. Menopause. 2024 Jan 1;31(1):68-76. doi: 10.1097/GME.0000000000002281. Epub 2023 Nov 27. Menopause. 2024. PMID: 38016166 Free PMC article.
IMPORTANCE: The neurokinin 3 receptor antagonist fezolinetant 45 mg/d significantly reduced frequency/severity of moderate to severe vasomotor symptoms (VMS) of menopause compared with placebo in two phase 3 randomized controlled trials. ...Tibolone 2.5 mg (t …
IMPORTANCE: The neurokinin 3 receptor antagonist fezolinetant 45 mg/d significantly reduced frequency/severity of moderate to severe …
Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms.
Onge ES, Phillips B, Miller L. Onge ES, et al. J Pharm Technol. 2023 Dec;39(6):291-297. doi: 10.1177/87551225231198700. Epub 2023 Sep 16. J Pharm Technol. 2023. PMID: 37974591 Free PMC article. Review.
Objective: To review the safety, efficacy, and tolerability of fezolinetant for the treatment of vasomotor symptoms associated with menopause. Data Sources: A literature search was conducted through PubMed using the following search terms: fezolinetant …
Objective: To review the safety, efficacy, and tolerability of fezolinetant for the treatment of vasomotor symptoms ass …
Fezolinetant for menopausal vasomotor symptoms.
[No authors listed] [No authors listed] Drug Ther Bull. 2024 Jul 29;62(8):118-124. doi: 10.1136/dtb.2024.000025. Drug Ther Bull. 2024. PMID: 39074999 Review. No abstract available.
Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.
Schaudig K, Wang X, Bouchard C, Hirschberg AL, Cano A, Shapiro C M M, Stute P, Wu X, Miyazaki K, Scrine L, Nappi RE. Schaudig K, et al. BMJ. 2024 Nov 18;387:e079525. doi: 10.1136/bmj-2024-079525. BMJ. 2024. PMID: 39557487 Free PMC article. Clinical Trial.
OBJECTIVES: To assess the efficacy and safety of the non-hormonal, neurokinin 3 receptor antagonist, fezolinetant, to treat moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy. ...CONCLUSIONS: Fezoline …
OBJECTIVES: To assess the efficacy and safety of the non-hormonal, neurokinin 3 receptor antagonist, fezolinetant, to treat moderate- …
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause.
Roberts MZ, Andrus MR. Roberts MZ, et al. Expert Opin Pharmacother. 2024 Jun;25(9):1131-1136. doi: 10.1080/14656566.2024.2375039. Epub 2024 Jul 8. Expert Opin Pharmacother. 2024. PMID: 38953697 Review.
Fezolinetant, a novel agent directly targeting the underlying pathophysiology of menopause-associated vasomotor symptoms, offers an alternative to hormonal therapies for which many patients have a contraindication or unwillingness to take due to safety concer …
Fezolinetant, a novel agent directly targeting the underlying pathophysiology of menopause-associated vasomotor symptoms …
121 results